Market Access Strategy for Medical Devices in Europe
Strategic recommendations on the topic of market access pathways for medical devices and IVD tests
White Paper: Market Access Landscape for Health Apps in Europe
Get insights from MTRC White Papers to explore practical strategies for navigating digital health reimbursement in Europe and discover how health app developers build effective strategies for market entry and scale
Recent news and posts
Three more health apps have obtained reimbursement in Germany since February 2024
In Germany, digital health applications (DiGAs) that can be prescribed by physicians and psychotherapists and reimbursed by statutory health insurers are listed in the Directory of Digital Health Applications maintained by the Federal Institute for Drugs and Medical Devices (BfArM). As of August 26, 2025, a total of 58 apps are available in the Directory and thus eligible for reimbursement.
Between early March and late August 2025, three new health apps were added to the Directory, all designed to support the management of attention deficit hyperactivity disorder (ADHD). Some examples are provided below.
The “ORIKO ADHS-Therapie” health app, introduced in the Directory on July 9, 2025, is intended for adults with ADHD. Its goal is to improve the quality of life, alleviate symptoms, and help patients cope with ADHD-related challenges in daily life. It also promotes health literacy and may help reduce comorbidities such as anxiety and depression. The program provides evidence-based psychological and psychotherapeutic methods, including mindfulness-based cognitive behavioral therapy (MBCT), psychoeducation (PE), cognitive behavioral therapy (CBT), dialectical behavioral therapy (DBT), and social skills training (SST). Available in German, it is priced at €479.70.
On August 6, 2025, the “attexis - die digitale Therapie bei ADHS im Erwachsenenalter” health app was introduced in the Directory. This app was developed by GAIA AG, Germany. It is designed for adults aged 18 years and older with ADHD, focusing primarily on delivering CBT methods and techniques. It is available in German at a tariff of €599.40.
The full details in German can be found here (attexis - die digitale Therapie bei ADHS im Erwachsenenalter) and here (ORIKO ADHS-Therapie).
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.